USPTO serial 79241657
Reviewed by CopyMark Law Group
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maurine Knutsson
Maurine Knutsson Knutsson IP ABNelinsgatan 14Norrkoping, 60345SWEDEN| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Substances for use in cell-based reporter gene assays, namely, assays for research purposes; reagents for medical research purposes; reagents for research purposes; reagents for industrial purposes, namely, reagents for scientific and research use; reagents for chemical analyses, namely, chemical reagents for non-medical purposes; cells and reagents for scientific and research use in testing of pharmaceutical products; cell culture media for scientific and research use, namely, cell-lines; components for cell-based analyses using optical methods and containing chemical reagents, namely, cells for scientific and research use; chemical preparations for the laboratory and for scientific, diagnostic and analytical purposes, other than for medical or veterinary use | ACTIVE | — |
| 005 | Reagents for medical use; diagnostic reagents for medical use; biological reagents for medical use; medical diagnostic reagents and assays for testing of body fluids; diagnostic and analytical substances for medical and veterinary purposes, in particular, laboratory diagnostic kits comprised of medical diagnostic reagents, anti-bodies, and immunochemicals for use in disease detection in the area of medical prevention | ACTIVE | — |
| 009 | [ Instruments for use in performing cell-based assays by means of optic detection, namely, optical inspection apparatus; computer software for use in performing optic based biological analysis; computer software for use in performing optic based biological analysis, and for using tools during drug development, clinical diagnosis, clinical monitoring or assay development; computer application software for mobile phones and handheld computers, namely, software for patient monitoring; apparatus for recording, transmission and reproduction of sound and images; blank magnetic data carriers; digital recording media, namely, blank digital storage media ] | SECTION 7(e) - CANCELLED | — |
| 010 | [ Medical diagnostic apparatus for testing assays; medical equipment, namely, apparatus for analysing blood ] | SECTION 71 - CANCELLED | — |
| 038 | [ Telecommunication services, namely, transmission of voice, data, graphics, images, audio and video by means of telecommunications networks, wireless communication networks, and the Internet; providing access to portals on the internet ] | SECTION 71 - CANCELLED | — |
| 042 | Cell-based assay services, namely, custom design and development of cell-based biochemical assays; cell-based assay services, namely, custom design and development of cell-based biochemical assays for use in drug development, clinical diagnosis, clinical monitoring or assay development; medical research; clinical research in the field of drug development, clinical diagnosis, clinical monitoring or assay development; scientific research; research and development in the field of diagnostic preparations; pharmaceutical drug development services; [ conducting clinical trials for others; ] laboratory research and analysis services in the field of drug development, clinical diagnosis, clinical monitoring or assay development; scientific laboratory testing services; [ research in the fields of medicine and data analytics; ] providing scientific diagnostic services for others in the fields of drug development, clinical diagnosis, clinical monitoring or assay development [ ; testing of chemical preparations and cells for diagnostic purposes ] | ACTIVE | — |
| 044 | Medical testing services relating to measurement and quantification of drug levels and immunogenicity in patient samples for diagnostic or treatment purposes [ ; medical services, namely, treating persons based on laboratory analysis; providing medical support in the nature of medical monitoring of patients receiving medical treatments; medical diagnostic testing services ] | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 17, 2026 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 17, 2025 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Jun 17, 2025 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Jun 16, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 7, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 25, 2025 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Jun 5, 2020 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Apr 15, 2020 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 2, 2020 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Sep 13, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 26, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 26, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 15, 2019 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Aug 15, 2019 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Aug 15, 2019 | PLGL | ASSIGNED TO PARALEGAL | — |
| Jul 30, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 30, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 12, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 8, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 1, 2019 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jan 23, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 23, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 23, 2019 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 3, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 29, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 28, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 28, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 9, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 23, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 23, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 12, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 11, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 11, 2018 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Oct 11, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 10, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 9, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 3, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 27, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |